Login to Your Account



Blood sample: Genentech hemophilia A data 'cells' Wall Street, uninhibited want for more

By Randy Osborne
Staff Writer

Thursday, December 22, 2016

The "beautiful, eloquent" research that led to emicizumab for hemophilia A will "dramatically change the way they live," Nancy Valente with Roche Holding AG unit Genentech told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription